Literature DB >> 10978511

Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells.

K Kato1, M Nomoto, H Izumi, T Ise, S Nakano, Y Niho, K Kohno.   

Abstract

STAT3 is involved in the signal transduction activated by various cytokines and growth factors. We found that the STAT3 gene is overexpressed in cisplatin-resistant cells. We isolated a genomic fragment containing the 5'-portion of the human STAT3 gene using a bubble PCR method. Using the bubble PCR product as a probe, one genomic clone was isolated. The nucleotide sequence of the first exon and the 1800 base pairs (bps) preceding it was determined. The promoter region of the human STAT3 gene is highly homologous to the corresponding region of the mouse STAT3 gene; several potential factor binding sites such as CRE/ATF, SBE, and GC boxes are also well conserved between human and mouse. A transient expression assay using the luciferase reporter gene showed that the sequence from -403 to +102 possesses maximal promoter activity, and transcription of the STAT3 gene was significantly higher in cisplatin-resistant cells than in parental cisplatin-sensitive cells. Deletion of the region between -261 and -167 resulted in significant loss of promoter activity in both parental and cisplatin-resistant cells. In vivo footprint analysis revealed several protein bindings; however, no significant differences were observed between drug-sensitive and drug-resistant cells. MNase digestion revealed that several open or active nucleosomes were only detected in cisplatin-resistant cells. These results suggest that STAT3 promoter function in a highly structured chromatin environment requires a complex interaction of several transcriptional factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978511     DOI: 10.1016/s0167-4781(00)00168-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  14 in total

1.  Specific immunotherapy generates CD8(+) CD196(+) T cells to suppress lung cancer growth in mice.

Authors:  Jian Zhang; Jing Liu; Huiguo Chen; Weibin Wu; Xiaojun Li; Yonghui Wu; Zhigang Wang; Kai Zhang; Yun Li; Yimin Weng; Hongying Liao; Lijia Gu
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

2.  Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.

Authors:  Derek Daigle; Cynthia Megyola; Ayman El-Guindy; Lyn Gradoville; David Tuck; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

3.  A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Authors:  Hui Xiao; Hemant Kumar Bid; David Jou; Xiaojuan Wu; Wenying Yu; Chenglong Li; Peter J Houghton; Jiayuh Lin
Journal:  J Biol Chem       Date:  2014-10-13       Impact factor: 5.157

4.  Benzyl Isothiocyanate (BITC) Induces Reactive Oxygen Species-dependent Repression of STAT3 Protein by Down-regulation of Specificity Proteins in Pancreatic Cancer.

Authors:  Ravi Kasiappan; Indira Jutooru; Keshav Karki; Erik Hedrick; Stephen Safe
Journal:  J Biol Chem       Date:  2016-11-15       Impact factor: 5.157

Review 5.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

6.  The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?

Authors:  Joelle Hillion; Surajit Dhara; Takita Felder Sumter; Mita Mukherjee; Francescopaolo Di Cello; Amy Belton; James Turkson; Souyma Jaganathan; Linzhao Cheng; Zhaohui Ye; Richard Jove; Peter Aplan; Ying-Wei Lin; Kelsey Wertzler; Ray Reeves; Ossama Elbahlouh; Jeanne Kowalski; Raka Bhattacharya; Linda M S Resar
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer.

Authors:  Suresh B Pakala; Suresh K Rayala; Rui-An Wang; Kazufumi Ohshiro; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Yi Zheng; Ricardo Pires; Sandra Casimiro; M Radhakrishna Pillai; Luis Costa; Rakesh Kumar
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

8.  Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate Stat3 at a posttranslational level in NIH3T3 cells.

Authors:  Hsuan-Heng Yeh; Chin-Han Wu; Raghavaraju Giri; Ken Kato; Kimitoshi Kohno; Hiroto Izumi; Cheng-Yang Chou; Wu-Chou Su; Hsiao-Sheng Liu
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

9.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

10.  ZNF341 controls STAT3 expression and thereby immunocompetence.

Authors:  Stefanie Frey-Jakobs; Julia M Hartberger; Manfred Fliegauf; Claudia Bossen; Magdalena L Wehmeyer; Johanna C Neubauer; Alla Bulashevska; Michele Proietti; Philipp Fröbel; Christina Nöltner; Linlin Yang; Jessica Rojas-Restrepo; Niko Langer; Sandra Winzer; Karin R Engelhardt; Cristina Glocker; Dietmar Pfeifer; Adi Klein; Alejandro A Schäffer; Irina Lagovsky; Idit Lachover-Roth; Vivien Béziat; Anne Puel; Jean-Laurent Casanova; Bernhard Fleckenstein; Stephan Weidinger; Sara S Kilic; Ben-Zion Garty; Amos Etzioni; Bodo Grimbacher
Journal:  Sci Immunol       Date:  2018-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.